Eton Pharmaceuticals (ETON) Other Accumulated Expenses (2023 - 2025)

Eton Pharmaceuticals (ETON) posted Other Accumulated Expenses of $675000.0 for Q1 2025, down 86.16% sequentially from $4.9 million in Q3 2024.

Eton Pharmaceuticals (ETON) Other Accumulated Expenses (2023 - 2025) Analysis & Trends

Eton Pharmaceuticals has reported Other Accumulated Expenses for 3 years, with the latest figure at $675000.0 in Q1 2025.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $675000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $675000.0 (changed N/A YoY) and the FY2023 annual result came in at $5.4 million, changed N/A from the prior year.
Other Accumulated Expenses slipped to $675000.0 in Q1 2025 per ETON's latest filing, from $4.9 million in the prior quarter.
Over five years, Other Accumulated Expenses peaked at $5.4 million in Q4 2023 and troughed at $675000.0 in Q1 2025.
A 3-year average of $3.6 million and a median of $4.9 million in 2024 frame the typical range for Other Accumulated Expenses.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	Eton Pharmaceuticals	1.65 Bn	1.62 Bn	25.41 Mn

Download Data